Spiriva® tiotropium
Long-acting anticholinergic

OVER DAILY
For the treatment of chronic obstructive pulmonary disease (COPD)

most prescribed COPD maintenance therapy worldwide

Spiriva® 28µg via HandiHaler®
Spiriva® Respimat® Soft Mist™ Inhaler 2.5µg (2 puffs, once daily)

2.5 µg (2 puffs, once daily)

Spiriva® 18 µg via HandiHaler®, twice-daily salmeterol 50µg via HFA-pMDI

Severe exacerbations are those resulting in hospitalisation

Once-daily Spiriva® 18µg via HandiHaler®, twice-daily salmeterol 50µg via HFA-pMDI

While Spiriva® 18µg via HandiHaler® did not alter the rate of decline in lung function, a coprimary endpoint, it sustained greater improvements in lung function vs. placebo

St George's Respiratory Questionnaire

References
1. IMS Health, IMS MIDAS(™), Q1 2014.

Spiriva® maintains

24-HR BRONCHODILATION
resulting in significant and sustained improvements in lung function

POET-COPD®

28% REDUCTION in risk of first severe exacerbation vs. placebo

UPLIFT®

1yr 2yrs 3yrs 4yrs
improved QUALITY OF LIFE 50% vs. placebo

References
1. IMS Health, IMS MIDAS(™), Q1 2014.